A Phase III, Dose-Response Evaluation of the Efficacy and Safety of CLONICEL® (Clonidine HCl Sustained Release) vs. Placebo in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00556959 Phase 3 COMPLETED

The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Details

Lead sponsor	Addrenex Pharmaceuticals, Inc.
Phase	Phase 3
Status	COMPLETED
Enrolment	236
Start date	2007-10
Completion	2008-08

Conditions

• Attention Deficit Disorder With Hyperactivity

Interventions

• high dose clonidine HCl sustained release
• low dose clonidine HCl sustained release
• placebo

Primary outcomes

• ADHDRS-IV — Week 5

Countries

United States